GlassScriptPhysician profile
Ryan David Skapyak
NPI 1699430058
$1,217.90
in general payments reported to CMS, 2019-2025
11 companies · $635 in 2025
The $635 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.16 · 2023: $218 · 2024: $351 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $435.02 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $293.06 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $187.98 | 2025 | Rezdiffra |
| Endogastric Solutions, INC | $85.86 | 2023 | Esophyx |
| Janssen Biotech, INC. | $54.98 | 2023-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $46.46 | 2023-2024 | Eohilia, Entyvio, Gattex |
| Novo Nordisk INC | $34.04 | 2022-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.27 | 2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $19.79 | 2023 | Linzess |
| Celgene Corporation | $16.23 | 2023 | Zeposia |
| Abbvie INC. | $15.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Skapyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.